Clinical trials: Hydroxychloroquine
COVID-19
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.
- Trial name
- HAHPS (NCT04329832)
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Intermountain Health Care, Inc.
Breast Cancer Stage IIB
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
- Trial name
- NCT03032406
- Testing
- Hydroxychloroquine, Everolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
COVID-19
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19
The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350 participants will be assigned to group that takes HCQ or group that opts to not take study medication.
- Trial name
- NCT04435808
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Tumor, Solid, Gastrointestinal Cancer
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies.
- Trial name
- NCT05221320
- Testing
- Ulixertinib, Hydroxychloroquine
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- BioMed Valley Discoveries, Inc
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Pancreatic Cancer
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
A standard treatment for patients with pancreatic cancer is standard photon radiation in combination with the chemotherapy drug, capecitabine.
- Trial name
- NCT01494155
- Testing
- Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04527549
- Testing
- Dabrafenib mesylate, Hydroxychloroquine, Trametinib dimethyl sulfoxide
- Where
- 199 sites in United States
- Volunteers
- 5 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Covid19, Progression
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.
- Trial name
- COVID-19 (NCT04491994)
- Testing
- HCQ
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- UNICEF
Prostate Cancer Recurrent
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of Hydroxychloroquine to the current treatment regimens.
- Trial name
- NCT04011410
- Testing
- Hydroxychloroquine Sulfate 200Mg Tab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Patrick Hensley
Chronic Kidney Disease, Cardiovascular Disease
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis
- Trial name
- MaCK (NCT03636152)
- Testing
- MRI carotid, APWV, Hydroxychloroquine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Pancreatic Cancer
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous.
- Trial name
- NCT01273805
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
HIV
Inducing Immune Quiescence to Prevent HIV Infection in Women
In this project, the investigators want to analyse the capacity of Acetylsalicylic acid and hydoxychlroquin (HCQ) to induce an Immune Quiescence (IQ) phenotype, which has been previously associated with natural protection to HIV…
- Trial name
- IIQ (NCT02079077)
- Testing
- Acetylsalicylic Acid (ASA), Hydroxychloroquine (HCQ)
- Where
- Kenya
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
SARS-CoV Infection, Covid19
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus.
- Trial name
- TriACT (NCT04605588)
- Testing
- Nitazoxanide, Ribavirin, Hydroxychloroquine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
Coronavirus, Acute Respiratory Infection
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19.
- Conditions
- Coronavirus, Acute Respiratory Infection, SARS-CoV Infection
- Trial name
- ORCHID (NCT04332991)
- Testing
- Hydroxychloroquine
- Where
- 40 sites in United States
- Volunteers
- 479 people
- Sponsor
- Massachusetts General Hospital
COVID-19
Treating COVID-19 With Hydroxychloroquine (TEACH)
Treatments for COVID-19 are urgently needed. Hydroxychloroquine (HCQ) is an antimalarial and immunomodulatory agent being repurposed for COVID-19 therapy based off in vitro data suggesting a possible antiviral effect.
- Trial name
- NCT04369742
- Testing
- Hydroxychloroquine (HCQ)
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- NYU Langone Health
Antiphospholipid Syndrome
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
- Trial name
- NCT01784523
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hospital for Special Surgery, New York
Lymphangioleiomyomatosis
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Specific Aim 1: To investigate whether, in Lymphangioleiomyomatosis (LAM) patients, the combination of sirolimus and hydroxychloroquine is safe and well tolerated Specific Aim 2: To investigate whether, in LAM patients, 6 months…
- Trial name
- SAIL (NCT01687179)
- Testing
- "Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital